Welcome and objectives - Luigi Costa, CEO

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Welcome and objectives - Luigi Costa, CEO"

Transcription

1 Welcome and objectives - Luigi Costa, CEO Market Capital Day, November 17 th 2015 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - 0

2 Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector s business, financial condition and results of operations. The terms anticipates, assumes, believes, can, could, estimates, expects, forecasts, intends, may, might, plans, should, projects, will, would or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1

3 Today s Objectives Discuss Nordic Nanovector s vision to become a leader in cancer care Develop a common understanding of Non-Hodgkin Lymphoma and B-cell tumours Learn about the role of Betalutin and how it can be developed to become a strong therapeutic alternative Meet with members of the Management Team and Board of Directors Ask questions 2

4 Nordic Nanovector: The emerging leader in cancer care Established in 2009 by Roy Larsen (Board member), Øyvind Bruland (M.D, PhD) and Jostein Dahle (CSO, Nordic Nanovector) Based on the Norwegian Radium Hospital s significant expertise in treating cancer Leveraging the unique Antibody Radionuclide Conjugate (ARC) technology Pipeline led by Betalutin for treating Non-Hodgkin Lymphoma (NHL), currently in Phase 2 Extend and improve the life of patients by developing and commercialising innovative Antibody Radionuclide Conjugates ARC 3

5 Strong Management Team soon to be completed with new Chief Medical Officer (CMO) Luigi Costa, Chief Executive Officer (CEO) More than 20 years of experience in the international pharmaceuticals and biotech industry Formerly VP of Europe, Middle East and Africa for Onyx Pharmaceuticals, various management positions with Amgen including head of International Oncology Franchise and general manager of Italy and France and various positions with Eli Lilly BSc in Business Administration from the University of Parma and an MBA from SDA Bocconi in Milan Tone Kvåle, Chief Financial Officer (CFO) More than 18 years of experience from the biotech industry Formerly CFO in NorDiag and senior management positions at Kavli Holding, Invitrogen/Life Technologies and Dynal Biotech Diploma in Finance and Administration from Harstad University College Marco Renoldi, MD, Chief Business Officer (CBO) Strong track record of commercial and financial results over 28 years of industry experience Has developed product lines and businesses, including start-ups, for established and innovative companies such as Novartis, Searle/Pharmacia, Amgen and Shionogi Medical degree and post-graduate studies in Child Neuropsychiatry from the University of Milan, and an MBA from Fondazione Istituto Dirigenti Italiani Jostein Dahle, Chief Scientific Officer (CSO) More than 15 years of experience in cancer research Formerly leader of the Radioimmunotherapy group at Institute for Cancer Research at the Norwegian Radium Hospital Ph.D. in radiation biology from University of Oslo and a M.Sc. in biophysics from Norwegian University for Science and Technology in Trondheim Co-founder of Nordic Nanovector Jan A. Alfheim, Chief Operations Officer (COO) 30 years of experience in the healthcare and chemical industries Formerly CBO at Clavis Pharma, Director of Business Development at Neurochem, President of Stempath and CEO of Nordic Nanovector M.Sc. in chemistry from Concordia University and a MBA from McGill University Anniken Hagen, Chief Quality Officer (CQO) More than 20 years of experience from the pharmaceutical industry with specialty in radiopharmacy Formerly Head of QA and QP at Norwegian Medical Cyclotron Centre, QC Manager at Algeta and scientist at Pronova Biomedical M.Sc. in radiochemistry from the University of Oslo 4

6 Board of Director with significant experience in early stage companies Ludvik Sandnes (Chairman) More than 40 years of experience from international corporate finance and investment banking as Executive Director and as strategic advisor from The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den norske Credtibank and Statoil Current board position, Oslo Cancer Cluster, IC-T AS, Pre-Diagnostics AS and Pioner Fonds AS Bachelor of Commerce and is a Certified European Financial Analyst (AFA) Roy Hartvig Larsen, Ph.D. Founder of Algeta and inventor of more than ten classes of patents/patent applications, including those related to Algeta s radium-223 and Thorium-227 technology Ph.D. and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo and Duke University MD and CSO of Algeta from Founder of and Chairman of the board of Nordic Nanovector from 2009 until 2014 Gisela M. Schwab, M.D Executive Vice President and Chief Medical Officer since January 2008 of Exelixis, Inc More than 23 years industry experience including senior positions at Abgenix and Amgen Current board position, Cellerant Therapeutics, Inc Doctor of Medicine degree from the University of Heidelberg. Board certified in internal medicine and haematology and oncology Per Samuelsson Partner at Odlander Fredrikson/HealthCap, joined in 2000 More than 15 years of investment banking experience, mainly with Aros Securities in Sweden Current board positions include BioStratum, Oncopeptides, Nordic Vision Clinics, RSPR, SwedenBIO and Targovax MSc in Engineering from the Institute of Technology in Linköping Hilde Hermansen Steineger, Ph. D. Head of Strategic Innovation Management, Nutrition & Health BASF Former positions include VP Investor Relations and Communications at Pronova BioPharma, Senior Associate with Neomed Management, independent advisor focusing on start-ups within the Life Science/Health Care sector, equity analyst at Kreditkassen (now Nordea Markets) and clinical research and international marketing at Nycomed Pharma Current board positions include Strongbridge BioPharma and PCI Biotech BSc and a PhD in Medical Biochemistry from the University of Oslo 5

7 Agenda Capital Market s Day 08:15-08:45 Registration: breakfast buffet upon arrival 08:45-08:55 Opening remarks CEO Luigi Costa 08:55-09:05 Welcome from the Board of Directors Chairman Ludvik Sandnes 09:05-09:50 The science behind Betalutin: why is it unique? Dr. Roy Larsen 09:50-10:35 The data behind Betalutin: reasons to believe Dr. Arne Kolstad 10:35-10:45 Q&A 10:45-10:55 Coffee break 10:55-11:40 What is NHL, how is it treated, what is the unmet need? Prof. Tim Illidge, BSc PhD MRCP FRCR FRCPath 11:40-12:25 Beginning with the goal in mind: our strategic approach CBO Marco Renoldi, MD to Betalutin s clinical development 12:25-12:45 Nordic Nanovector strategic outlook & vision CEO Luigi Costa 12:45-13:00 Closing remarks and Q&A CEO Luigi Costa 13:00-14:00 End of meeting: lunch upon departure 6

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Tone Kvåle, Chief Financial Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com

More information

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation

More information

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based

More information

improving nature s own defense mechanisms Company presentation

improving nature s own defense mechanisms Company presentation improving nature s own defense mechanisms Company presentation August 2013 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Aims to develop novel therapeutics for areas of high unmet

More information

Scandinavian Bio-Business Seminar, Zürich. Presentation 10 February 2016 Håkon Sæterøy, CEO

Scandinavian Bio-Business Seminar, Zürich. Presentation 10 February 2016 Håkon Sæterøy, CEO Scandinavian Bio-Business Seminar, Zürich Presentation 10 February 2016 Håkon Sæterøy, CEO Clinical need 75 m patients WW A global estimate of 75m patients with Mild Cognitive Impairment (MCI) who may

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY

PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY RESULTS OF THE FIRST QUARTER 2013 25 April 2013 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation

More information

PCI Biotech Holding ASA - Second Quarter Report 2008

PCI Biotech Holding ASA - Second Quarter Report 2008 PCI Biotech Holding ASA - Second Quarter Report 2008 Highlights Demerger and Initial Public Offering at Oslo Axess in June Raised NOK 60 million Per Walday, PhD hired as new CEO Board has been strengthened

More information

Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa

Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma DNB Healthcare Conference 2015: CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com 1

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic.

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic. DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com www.diagenic.com DiaGenic ASA Slide #1 UK Press Coverage Slide #2 Markets: Large, fast growing. Unmet medical

More information

The world leader in photodynamic technology

The world leader in photodynamic technology Brilliance in photodynamic technology TM The world leader in photodynamic technology Presentation of third quarter 2010 results 27 October 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO The

More information

Summary published in connection to the admission to trading of shares in - Algeta ASA on NASDAQ OMX Stockholm

Summary published in connection to the admission to trading of shares in - Algeta ASA on NASDAQ OMX Stockholm Summary published in connection to the admission to trading of shares in - Algeta ASA on NASDAQ OMX Stockholm This summary is entirely based on information available in Algeta ASA (also referred to as

More information

Nordic IR Conference Oslo, 9 June 2015

Nordic IR Conference Oslo, 9 June 2015 Nordic IR Conference Oslo, 9 June 2015 Nordic IR Conference in Oslo - 9 June 2015 Optimising the Impact of your IR Strategy NIRA (Norwegian Investor Relations Association) and Oslo Børs have great pleasure

More information

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Selling an Idea Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Seminar Format XXXX Know Your Stuff Andy Murray The Beetles Read everything in your field Keep up to date Be dedicated

More information

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS News Release POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,

More information

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education Curriculum Vitae Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details Private Address: Date, Place of Birth: Marital Status: Nationality: Languages: Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49

More information

Prospectus. Nordic Nanovector AS

Prospectus. Nordic Nanovector AS Prospectus Nordic Nanovector AS (A private limited company incorporated under the laws of Norway) Offering of up to 2,000,000 Subsequent Offering Shares with Subscription Rights for Eligible Shareholders

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

Main Conference Agenda

Main Conference Agenda Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental

More information

An Exclusive Interview with Dr Jan-Anders Karlsson

An Exclusive Interview with Dr Jan-Anders Karlsson Dr Jan-Anders Karlsson took over the helm as the CEO of S*BIO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr Karlsson

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation J.P. Morgan Healthcare Conference McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer January 13, 2015 Forward-Looking Statements Some of the information in this presentation is not

More information

Clinical Research from EHR data

Clinical Research from EHR data Clinical Research from EHR data Gunnar O Klein professor in Health Informatics at NSEP Norwegian Centre for EHR Research Workshop at HelseIT in Trondheim 2012-09-19 1 Purpose of the workshop Together with

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Biosimilars 20/20. The Future is at Hand

Biosimilars 20/20. The Future is at Hand Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Anne is a Chartered Accountant and holds a Bachelor of Economics from University of Sydney.

Anne is a Chartered Accountant and holds a Bachelor of Economics from University of Sydney. MANAGEMENT COMMITTEE Updated May 2016 Anne Bell - Chief Financial Officer As Chief Financial Officer, Anne directs the finance operations at the group level as well as managing the tax, treasury, supply

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences NASDAQ: CLRB September 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation

More information

Vegenics. a global cancer initiative. circadian. biocreator

Vegenics. a global cancer initiative. circadian. biocreator Vegenics a global cancer initiative DISCLAIMER Investment in Circadian Technologies Limited ( Circadian ) is subject to investment risk, including possible loss of income and capital invested. Neither

More information

improving nature s own defense mechanisms Shareholder meetings

improving nature s own defense mechanisms Shareholder meetings improving nature s own defense mechanisms Shareholder meetings April 2015 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Technology platform- de novo designed host defence peptides

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Egon Zehnder International

Egon Zehnder International Egon Zehnder I. ID info about yourself Work-setting Preferences Personal Skills Inventory Motivational Factors III. Targeting your employer Narrowing the field Aligning credentials Optimizing documents

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

Company announcement no. 12/2014 September 8, 2014

Company announcement no. 12/2014 September 8, 2014 page 1 of 6 Company announcement no. 12/2014 September 8, 2014 Cheminova to be sold to FMC Corporation Combined business will have greater scale, geographic balance, and a broader portfolio of complementary

More information

Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology

Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology Actionable Insights into Health Policy, Practice and Outcomes Through Research and Big Data - with a Spotlight on Oncology Attend the Virtual Meeting in HE-Xpo Wednesday, Feb. 18, 2015 Session One: 9:30

More information

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a

More information

Philips Capital Markets Day -Group -Healthcare

Philips Capital Markets Day -Group -Healthcare Philips Capital Markets Day -Group -Healthcare Boston, May 10, 2012 Important information Forward-looking statements This document and the related oral presentation, including responses to questions following

More information

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory

More information

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported

More information

Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017

Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017 Developing First-in-Class Treatments in Haematologic Cancers Biotech Showcase 2017, San Francisco, January 9 th 2017 \\AD.JEFCO.COM\BANKING\HEALTHCARE INTL\DEALS\NOR45600IB - TARGET\2. FROM COMPANY\011216

More information

CV - Curriculum Vitae

CV - Curriculum Vitae Bengt Arne Sjöqvist Born: August 8, 1952 Family: Engaged, 2 children born 1988 and 1991 Adress: Tärneskärsgatan 28, 421 57 Västra Frölunda, Sweden Tel. +46 31-709 86 26 (private) +46 70-787 77 97 (mobile)

More information

UDG Healthcare plc An International Healthcare Services Organisation

UDG Healthcare plc An International Healthcare Services Organisation UDG Healthcare plc An International Healthcare Services Organisation Jefferies 2014 Global Healthcare Conference 2014 Liam FitzGerald, CEO 20 November 2014 1 FORWARD LOOKING STATEMENTS Some statements

More information

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter)

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

NEW STRATEGIES FOR GROWTH

NEW STRATEGIES FOR GROWTH OTCQX: LMRMF INFO@LOMIKO.COM NEW STRATEGIES FOR GROWTH Forward-looking Statements Advisory This document may contain "forward-looking statements" within the meaning of Canadian securities legislation.

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

_Regulatory & Quality Compliance Graduate Certificate Program

_Regulatory & Quality Compliance Graduate Certificate Program _Regulatory & Quality Compliance Graduate Certificate Program An Important Three Course Program Presented by Purdue University, West Lafayette, IN Instructors: S. Byrn, M. Schmidt, and T. Wilson With emphasis

More information

Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences NASDAQ: CLRB October 2015 1 Safe Harbor Statement This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation

More information

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013

CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013 CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT EXECUTIVE SUMMARY April 2013 Copyright CMO Council. All Rights Reserved. 2013 ABSTRACT Change and transformation have become common occurrences if not required

More information

WILEX AG: Interim management statement on the first quarter of 2016

WILEX AG: Interim management statement on the first quarter of 2016 WILEX AG: Interim management statement on the first quarter of 2016 Munich, Germany, 14 April 2016. WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today reported on the first three months of the 2016 financial

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Centrale-Santé: The Professional Healthcare and biotech Think Tank Professional Group Centrale Alumni Association

Centrale-Santé: The Professional Healthcare and biotech Think Tank Professional Group Centrale Alumni Association Centrale-Santé: The Professional Healthcare and biotech Think Tank Professional Group Centrale Alumni Association Centrale-Santé Presentation 2010 www.centrale-sante.net 1 Centrale-Santé at a glance The

More information

Game-Changing Industry Leadership

Game-Changing Industry Leadership Game-Changing Industry Leadership NASDAQ: HIIQ Third Quarter 2015 Disclosure Certain statements included herein, including those that express management s expectations or estimates of Health Insurance

More information

16 February 2012 Fourth Quarter 2011 CEO Sverre Hurum CFO Erik Stubø

16 February 2012 Fourth Quarter 2011 CEO Sverre Hurum CFO Erik Stubø 16 February 2012 Fourth Quarter 2011 CEO Sverre Hurum CFO Erik Stubø Disclaimer The information contained in the Presentation is for your use only. Recipients may not reproduce, redistribute or pass on,

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

Orion Corporation. Jefferies Healthcare Conference New York 9 June Tuukka Hirvonen Manager, Investor Relations

Orion Corporation. Jefferies Healthcare Conference New York 9 June Tuukka Hirvonen Manager, Investor Relations Orion Corporation Jefferies Healthcare Conference New York 9 June 2016 Tuukka Hirvonen Manager, Investor Relations Forward-looking statements This presentation contains forward-looking statements which

More information

Interim report Second quarter 2015

Interim report Second quarter 2015 Interim report Second quarter 2015 Oslo, 20 August 2015 Presenters and agenda Agenda Hans-Petter Mellerud Founder and CEO Highlights for the quarter Financial performance Regional trends Nina Stemshaug

More information

Snap Interactive, Inc. (OTCQB: STVI) Pro Forma Financial Highlights & Strategy Update December 19, 2016

Snap Interactive, Inc. (OTCQB: STVI) Pro Forma Financial Highlights & Strategy Update December 19, 2016 Snap Interactive, Inc. (OTCQB: STVI) Pro Forma Financial Highlights & Strategy Update December 19, 2016 Safe Harbor This presentation is for discussion purposes only. The material is based upon information

More information

Medical & Health Sciences

Medical & Health Sciences School of Postgraduate Studies Medical & Health Sciences (MSc /PhD by Research) 2016 What Is IMU s Medical & Health Sciences (by Research) Programme About? Overview Postgraduate research forms a major

More information

Health Care Administrator

Health Care Administrator Health Care Administrator At a Glance Health care administrators work behind the scenes at hospitals and other medical facilities, making sure they run smoothly. Search by Cluster Medical & Health Typical

More information

Baxalta 2015 Investor Conference May 19, 2015

Baxalta 2015 Investor Conference May 19, 2015 Eric W. Foster is expected to serve as Senior Vice President and Chief Information Officer for Baxalta upon completion of the separation. Mr. Foster brings more than 15 years of IT leadership experience

More information

Job Opportunities at the Cell Therapy Catapult

Job Opportunities at the Cell Therapy Catapult Job Opportunities at the Cell Therapy Catapult The Cell Therapy Catapult is a centre of excellence for regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery

More information

Solar Day A rapidly growing market what now, Norway? l 10 FEBRUARY 2016 l MULTICONSULT l NEDRE SKØYEN VEI 2 l OSLO l. In cooperation with:

Solar Day A rapidly growing market what now, Norway? l 10 FEBRUARY 2016 l MULTICONSULT l NEDRE SKØYEN VEI 2 l OSLO l. In cooperation with: Solar Day 2016 A rapidly growing market what now, Norway? l 10 FEBRUARY 2016 l MULTICONSULT l NEDRE SKØYEN VEI 2 l OSLO l In cooperation with: Norwegian solar industry will it grow with the rapidly growing

More information

Philips Capital Markets Day -Group -Healthcare

Philips Capital Markets Day -Group -Healthcare Philips Capital Markets Day -Group -Healthcare Boston, March 19, 2013 Important information Forward-looking statements This document and the related oral presentation, including responses to questions

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

Presentation of second quarter 2010 results

Presentation of second quarter 2010 results Brilliance in photodynamic technology TM Building a Specialty Pharma company Presentation of second quarter 2010 results 19 August 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO Photocure is

More information

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES

BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES BUSINESS OPPORTUNITIES IN BIOTECHNOLOGY, PHARMACY AND LIFE SCIENCES HEALTHCARE BIOTECHNOLOGY In Spain the development of ageing medicine presents an excellent business opportunity because the population

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

Health IT in Alberta & Beyond Analytics, Informatics & Innovation

Health IT in Alberta & Beyond Analytics, Informatics & Innovation Health IT in Alberta & Beyond Analytics, Informatics & Innovation Special Thanks to Sponsors: February 5, 2015 Delta Calgary South 135 Southland Dr SE Calgary, Alberta Individual Conference Presenting

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

R&D audit at LEO Pharma

R&D audit at LEO Pharma p. 01 R&D audit at LEO Pharma 1 st May 2013 Background Group Danish parent company p. 02 Research-based pharmaceutical company specialising in Dermatological and Thrombosis products Founded in 1908 No

More information

LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT

LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT The Manager Company Announcements Office ASX Limited LBT INNOVATIONS TO PRESENT AT AUSBIOTECH BROKER MEETS BIOTECH EVENT Adelaide, Australia, 22 September 2016: The newly-appointed Chief Executive Officer

More information

TABLE OF CONTENTS ABOUT MARTINSEN MAYER 2 ABOUT THE SURVEY 2 GENERAL TRENDS MOUNA KENZAOUI, CEO 3 EXECUTIVE 4 ACCOUNTANCY AND FINANCE 6 BANKING 8

TABLE OF CONTENTS ABOUT MARTINSEN MAYER 2 ABOUT THE SURVEY 2 GENERAL TRENDS MOUNA KENZAOUI, CEO 3 EXECUTIVE 4 ACCOUNTANCY AND FINANCE 6 BANKING 8 TABLE OF CONTENTS ABOUT MARTINSEN MAYER 2 ABOUT THE SURVEY 2 GENERAL TRENDS MOUNA KENZAOUI, CEO 3 EXECUTIVE 4 ACCOUNTANCY AND FINANCE 6 BANKING 8 LEGAL 10 HUMAN RESOURCES 11 TECHNOLOGY 13 SALES 17 MARKETING

More information

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 HORIZON PHARMA PLC FORM 8-K (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 Telephone 011-353-1-772-2100 CIK 0001492426 Symbol HZNP SIC Code 2834 - Pharmaceutical Preparations Industry

More information

Immune Pharmaceuticals Announces Corporate Update; Second Quarter 2015 Financial Results and Highlights and Conference Call Details

Immune Pharmaceuticals Announces Corporate Update; Second Quarter 2015 Financial Results and Highlights and Conference Call Details Immune Pharmaceuticals Announces Corporate Update; Second Quarter 2015 Financial Results and Highlights and Conference Call Details NEW YORK, August 17, 2015 /PRNewswire/ -- Immune Pharmaceuticals, Inc.

More information

Biomedical Business: Current Trends, Product Challenges and Future Outlook

Biomedical Business: Current Trends, Product Challenges and Future Outlook Biomedical Business: Current Trends, Product Challenges and Future Outlook Prepared and Presented by Audrey S. Erbes, Ph.D. Principal, Erbes & Associates Life Science Marketing and Business Development

More information

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management

Investors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management OCTOBER 5-6, 2015 PARIS, FRANCE 6 th EDITION THE LEADING PARTNERING MEETING IN OPEN INNOVATION FOR LIFE SCIENCES CONFERENCES EXHIBITION HALL ONE-ON-ONE PARTNERING MEETINGS NETWORKING Open PRELIMINARY PROGRAM

More information

STATEMENT OF THE AUSTRALIAN AND NEW ZEALAND SOCIETY OF RESPIRATORY SCIENCE GUIDELINES FOR QUALIFICATIONS OF CLINICAL RESPIRATORY LABORATORY

STATEMENT OF THE AUSTRALIAN AND NEW ZEALAND SOCIETY OF RESPIRATORY SCIENCE GUIDELINES FOR QUALIFICATIONS OF CLINICAL RESPIRATORY LABORATORY STATEMENT OF THE AUSTRALIAN AND NEW ZEALAND SOCIETY OF RESPIRATORY SCIENCE GUIDELINES FOR QUALIFICATIONS OF CLINICAL RESPIRATORY LABORATORY SCIENTISTS Gary Nolan 1,3,4, Stephen West 2, Debbie Burton 3

More information

For personal use only

For personal use only ASX.OSL Advancing Pancreatic & Liver Cancer Treatment CEO Presentation 18 October 2016 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Weifa ASA Second quarter and first half 2016 Third quarter 2015

Weifa ASA Second quarter and first half 2016 Third quarter 2015 Weifa ASA Second quarter and first half 2016 Third quarter 2015 Kathrine Gamborg Andreassen (CEO) and Simen Nyberg-Hansen (CFO) 25 August 2016 1 Presentation outline Highlights I Operational performance

More information

Future In Life Sciences

Future In Life Sciences Future In Life Sciences Event Series Sponsorship Overview About the Partnership Propel Careers, MassBio, and the MassBioEd joined together in 2011 to organize a series of networking and panel events focused

More information

Making Vestas profitable - Ensuring delivery. By Dag Andresen, Executive Vice President and CFO

Making Vestas profitable - Ensuring delivery. By Dag Andresen, Executive Vice President and CFO Making Vestas profitable - Ensuring delivery By Dag Andresen, Executive Vice President and CFO Introducing myself and my background Dag Andresen Group Chief Financial Officer (CFO), Executive Vice President,

More information

Click to edit Master title style. Investor Presentation. September 12, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc.

Click to edit Master title style. Investor Presentation. September 12, 2016. nuvopharmaceuticals.com TSX: NRI Nuvo Pharmaceuticals Inc. Click to edit Master title style Investor Presentation September 12, 2016 nuvopharmaceuticals.com Nuvo Pharmaceuticals Inc. Click Safe Harbour to edit Master title style Certain information to be discussed

More information

To be taught at the Ausia Biotech Aseptic Training Center in Hangzhou China

To be taught at the Ausia Biotech Aseptic Training Center in Hangzhou China Come learn from our 3-day course! Introduction to Aseptic Processing To be taught at the Ausia Biotech Aseptic Training Center in Hangzhou China March 23-25, 2016 1. Introduction to TPA-IT: China s only

More information

Spinnovator Public Private Partnership for Spin-offs

Spinnovator Public Private Partnership for Spin-offs A project of Ascenion and Vesalius Biocapital supported by the BMBF 5th International VPM Days Hannover Spinnovator Public Private Partnership for Spin-offs Christian Stein, September 1, 2011 Ascenion

More information

2016 Scotiabank Financials Summit R. Jeffrey Orr President & CEO, Power Financial. September 8, 2016

2016 Scotiabank Financials Summit R. Jeffrey Orr President & CEO, Power Financial. September 8, 2016 2016 Scotiabank Financials Summit R. Jeffrey Orr President & CEO, Power Financial September 8, 2016 Forward Looking Statements In the course of today s meeting, officers of the Corporation may make, in

More information

SCICLONE PHARMACEUTICALS INC

SCICLONE PHARMACEUTICALS INC SCICLONE PHARMACEUTICALS INC FORM 8-K (Current report filing) Filed 11/09/16 for the Period Ending 11/09/16 Address 950 TOWER LANE SUITE 900 FOSTER CITY, CA 94404-2125 Telephone 650-358-3456 CIK 0000880771

More information

Qualifications for Healthcare Facility Radiation Safety Officer

Qualifications for Healthcare Facility Radiation Safety Officer Standards of Qualification and Practice (SQ/P) Qualifications for Healthcare Facility Radiation Safety Officer Medical Health Physics Section American Academy of Health Physics and Medical Health Physics

More information

Fachgruppe Drug Delivery

Fachgruppe Drug Delivery industrial career at Beiersdorf-Lilly GmbH, Hamburg Bernd Riebesehl, Ph. D. completed his thesis on solubilization at the TU Braunschweig in 1992. He started his leading a lab for preformulation and line

More information

Program Details. 12:00 12:45 Networking Lunch & Registration. 12:45 12:50 Welcome & Introduction

Program Details. 12:00 12:45 Networking Lunch & Registration. 12:45 12:50 Welcome & Introduction The Heart of America Chapter Presents: CEO/CFO Leadership Forum November 16 th, 2010 Ritz Charles 9000 West 137th Street, Overland Park, KS 66221 Networking Lunch 12:00-12:45 pm Program: 12:45 4:00 pm

More information

Fourth Quarter 2010 CEO Sverre Hurum CFO Erik Stubø

Fourth Quarter 2010 CEO Sverre Hurum CFO Erik Stubø Fourth Quarter 2010 CEO Sverre Hurum CFO Erik Stubø 18 February 2011 Disclaimer The information contained in the Presentation is for your use only. Recipients may not reproduce, redistribute or pass on,

More information

September 29, About BIO

September 29, About BIO The Comments of the Biotechnology Industry Organization on the Discussion Paper on Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce

More information